MX2022001958A - Sal. - Google Patents
Sal.Info
- Publication number
- MX2022001958A MX2022001958A MX2022001958A MX2022001958A MX2022001958A MX 2022001958 A MX2022001958 A MX 2022001958A MX 2022001958 A MX2022001958 A MX 2022001958A MX 2022001958 A MX2022001958 A MX 2022001958A MX 2022001958 A MX2022001958 A MX 2022001958A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- diphenylpyrazin
- butoxy
- isopropyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a una nueva sal de ácido 2-(4-((5,6-difenilpirazin-2-il)(isopropil)amino)butoxi)acético (de ahora en más mencionada como "Compuesto B") y un cristal de su sal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019149945 | 2019-08-19 | ||
PCT/JP2020/031204 WO2021033702A1 (en) | 2019-08-19 | 2020-08-19 | Salt |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001958A true MX2022001958A (es) | 2022-03-11 |
Family
ID=74660858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001958A MX2022001958A (es) | 2019-08-19 | 2020-08-19 | Sal. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220281830A1 (es) |
EP (1) | EP4021896A4 (es) |
JP (1) | JP2022545195A (es) |
KR (1) | KR20220049565A (es) |
CN (1) | CN114206842A (es) |
AR (1) | AR120073A1 (es) |
AU (1) | AU2020333633A1 (es) |
BR (1) | BR112022002648A2 (es) |
CA (1) | CA3151831A1 (es) |
CL (1) | CL2022000370A1 (es) |
CO (1) | CO2022002865A2 (es) |
EC (2) | ECSP22021103A (es) |
IL (1) | IL290692A (es) |
MX (1) | MX2022001958A (es) |
PE (1) | PE20220969A1 (es) |
TW (1) | TW202114998A (es) |
UY (1) | UY38848A (es) |
WO (1) | WO2021033702A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202241425A (zh) * | 2021-01-29 | 2022-11-01 | 瑞士商艾克泰聯製藥有限公司 | 用於製造二苯基吡𠯤衍生物之程序 |
TW202239408A (zh) * | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
TW202404594A (zh) * | 2022-06-10 | 2024-02-01 | 日商日本新藥股份有限公司 | 醫藥組合物 |
WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI316055B (es) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
WO2011024874A1 (ja) * | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
WO2018019296A1 (zh) * | 2016-07-29 | 2018-02-01 | 成都苑东生物制药股份有限公司 | 氨基吡嗪类化合物或盐、异构体、其制备方法及用途 |
WO2019065792A1 (ja) * | 2017-09-28 | 2019-04-04 | 日本新薬株式会社 | 結晶 |
-
2020
- 2020-08-19 JP JP2022509639A patent/JP2022545195A/ja active Pending
- 2020-08-19 MX MX2022001958A patent/MX2022001958A/es unknown
- 2020-08-19 AU AU2020333633A patent/AU2020333633A1/en active Pending
- 2020-08-19 EP EP20853818.1A patent/EP4021896A4/en active Pending
- 2020-08-19 AR ARP200102335A patent/AR120073A1/es unknown
- 2020-08-19 BR BR112022002648A patent/BR112022002648A2/pt unknown
- 2020-08-19 TW TW109128278A patent/TW202114998A/zh unknown
- 2020-08-19 UY UY0001038848A patent/UY38848A/es unknown
- 2020-08-19 CA CA3151831A patent/CA3151831A1/en active Pending
- 2020-08-19 US US17/635,710 patent/US20220281830A1/en active Pending
- 2020-08-19 CN CN202080058495.7A patent/CN114206842A/zh active Pending
- 2020-08-19 KR KR1020227008980A patent/KR20220049565A/ko active Search and Examination
- 2020-08-19 WO PCT/JP2020/031204 patent/WO2021033702A1/en active Application Filing
- 2020-08-19 PE PE2022000275A patent/PE20220969A1/es unknown
-
2022
- 2022-02-15 CL CL2022000370A patent/CL2022000370A1/es unknown
- 2022-02-17 IL IL290692A patent/IL290692A/en unknown
- 2022-03-11 CO CONC2022/0002865A patent/CO2022002865A2/es unknown
- 2022-03-18 EC ECSENADI202221103A patent/ECSP22021103A/es unknown
-
2024
- 2024-01-16 EC ECSENADI20243395A patent/ECSP24003395A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020333633A1 (en) | 2022-03-17 |
CA3151831A1 (en) | 2021-02-25 |
EP4021896A1 (en) | 2022-07-06 |
CL2022000370A1 (es) | 2022-11-04 |
ECSP22021103A (es) | 2022-04-29 |
US20220281830A1 (en) | 2022-09-08 |
KR20220049565A (ko) | 2022-04-21 |
UY38848A (es) | 2021-02-26 |
CO2022002865A2 (es) | 2022-08-30 |
WO2021033702A1 (en) | 2021-02-25 |
IL290692A (en) | 2022-04-01 |
ECSP24003395A (es) | 2024-02-29 |
EP4021896A4 (en) | 2023-08-23 |
AR120073A1 (es) | 2022-02-02 |
CN114206842A (zh) | 2022-03-18 |
JP2022545195A (ja) | 2022-10-26 |
BR112022002648A2 (pt) | 2022-07-12 |
PE20220969A1 (es) | 2022-06-10 |
TW202114998A (zh) | 2021-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001958A (es) | Sal. | |
MX2020009948A (es) | Amidas heterocíclicas útiles como moduladores de proteínas. | |
RS54653B1 (en) | 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT | |
MX2022016515A (es) | Nuevo inhibidor de la secrecion de acido y uso del mismo. | |
RS54445B1 (en) | 3,5-DIAMINO-6-CHLORO-N- (N- (4- (4- (2- (HEXYL (2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) ETHOXY) PHENYL) BUTYL) CARBAMIMIDOIL) PYRAZINE -2-CARBOXAMIDE | |
CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
MX2020011845A (es) | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. | |
AU2018274378A1 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
WO2018153508A3 (en) | INHIBITORS OF SULFOXIMINE GLYCOSIDASE | |
MX2021007017A (es) | Inhibidor de la 15-pgdh. | |
MX2020011671A (es) | Nuevo proceso para la preparacion de diamidas antranilicas. | |
WO2021079196A3 (en) | Mettl3 modulators | |
EA200400414A1 (ru) | Кристаллические гидраты производных анилида никотиновой кислоты | |
SG11201810725WA (en) | Novel β-lactamase inhibitors | |
MX2022012998A (es) | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico. | |
MX2023009037A (es) | Compuesto de pirimidopirano. | |
NZ774126A (en) | Spd-1 variant - fc fusion proteins | |
EP4169925A3 (en) | Process to make n-substituted tetrahydrothienopyridine derivatives | |
MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
MX2021009261A (es) | Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. | |
MX2021007511A (es) | Procedimiento para la preparacion de anilinas sustituidas. | |
MX2021015214A (es) | Compuestos para tratar enfermedad respiratoria. | |
WO2020003272A8 (en) | An improved process for the preparation of venetoclax | |
CR20210148A (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
PE20171349A1 (es) | Inhibidores de bace1 |